NR4A1 and neoplasm: A (final) pathologic node-negative status was seen in 56% (5/9) of patients with hormone receptor positive / HER2 positive breast cancer, in 48% (84/175) of cases with a hormone receptor positive / HER2 negative tumor, in 0% (0/4) of cases with a hormone receptor negative / HER2 positive tumor and in 74% (31/42) of cases with a hormone receptor negative / HER2 negative (triple negative) breast tumor.